Pennant Group, Inc. PNTG
The Pennant Group, Inc. is a leading provider of high-quality healthcare services to patients, residents, and clients of all ages, including the growing senior population, in the United States. We strive to be the provider of choice in the communities we serve through our innovative operating model and unique core values.
As of December 31, 2025, we operate in multiple lines of business, including home health, hospice, and senior living services across Alabama, Arizona, California, Colorado, Georgia, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin and Wyoming. We also provide home health and hospice operational support through a management service agreement in Connecticut. We provide home health and hospice services through 172 agencies, and senior living services at 63 communities with 4,428 total units in our assisted living, independent living and memory care business. We derive revenue from a diversified blend of payors including Medicare and Medicaid programs, private pay patients and residents, and managed care payors.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $947.7M | $695.2M | $544.9M | $473.2M | $439.7M | $391.0M | $338.5M | $286.1M | $251.0M | — |
| SG&A | $71.1M | $50.2M | $36.7M | $34.0M | $36.3M | — | — | — | — | — |
| Total operating expenses | $895.8M | $657.1M | $519.7M | $460.5M | $435.0M | $372.0M | $332.9M | $265.4M | $235.6M | — |
| Operating income | $51.9M | $38.1M | $25.2M | $12.7M | $4.7M | $18.9M | $5.7M | $20.6M | $15.4M | — |
| Interest expense | $6.7M | $7.0M | $5.9M | $3.8M | $1.9M | $1.2M | $410.0K | $0 | — | — |
| Pre-tax income | $45.6M | $31.4M | $19.6M | $8.9M | $2.7M | $17.9M | $5.3M | $20.6M | $15.4M | — |
| Income tax | $11.9M | $7.0M | $5.7M | $1.6M | $582.0K | $2.4M | $2.1M | $4.4M | $5.4M | — |
| Net income | $29.6M | $22.6M | $13.4M | $6.6M | $2.7M | $15.7M | $2.5M | $15.7M | $9.9M | — |
| EPS, basic | 0.86 | 0.72 | 0.45 | 0.23 | 0.09 | 0.56 | 0.11 | 0.58 | 0.36 | — |
| EPS, diluted | 0.84 | 0.70 | 0.44 | 0.22 | 0.09 | 0.52 | 0.11 | 0.58 | 0.36 | — |
| Shares, diluted (wtd. avg.) | $35.3M | $32.0M | $30.2M | $30.2M | $30.6M | $30.2M | $29.6M | $27.8M | $27.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.0M | $24.2M | $6.1M | $2.1M | $5.2M | $43.0K | $402.0K | $41.0K | $36.0K | $30.0K |
| Receivables | $123.1M | $81.3M | $61.1M | $53.4M | $53.9M | $47.2M | $32.2M | $24.5M | — | — |
| Total current assets | $167.4M | $122.9M | $80.1M | $73.8M | $75.8M | $59.6M | $38.7M | $29.1M | — | — |
| Property, plant and equipment | $61.0M | $43.3M | $28.6M | $26.6M | $16.8M | $17.9M | $14.6M | $10.5M | — | — |
| Goodwill | $237.2M | $129.1M | $91.0M | $79.5M | $74.3M | $66.4M | $41.2M | $30.9M | $28.0M | — |
| Other intangibles | — | — | — | — | — | — | $45.0K | $78.0K | — | — |
| Total assets | $968.2M | $679.5M | $539.7M | $512.1M | $530.3M | $507.0M | $447.8M | $98.2M | — | — |
| Accounts payable | $25.2M | $18.7M | $10.8M | $13.6M | $10.6M | $9.8M | $8.7M | $4.4M | — | — |
| Short-term debt | $5.0M | $0 | — | — | — | — | — | — | — | — |
| Total current liabilities | $147.3M | $101.7M | $71.5M | $70.2M | $71.6M | $89.0M | $51.2M | $29.5M | — | — |
| Long-term debt | $168.8M | $0 | $63.9M | $62.9M | $51.4M | $8.3M | $18.5M | $0 | — | — |
| Total liabilities | $593.9M | $367.6M | $394.2M | $386.5M | $416.1M | $405.8M | $376.6M | $32.9M | — | — |
| Retained earnings | $86.8M | $57.2M | $34.7M | $21.3M | $14.6M | $11.9M | -$3.8M | $0 | — | — |
| Total equity | $374.3M | $312.0M | $145.5M | $125.7M | $114.2M | $101.2M | $71.1M | $65.3M | $59.9M | $48.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $48.3M | $39.3M | $33.1M | $9.0M | -$18.2M | $50.2M | $9.6M | $23.3M | $17.2M | — |
| Depreciation and amortisation | $8.5M | $6.1M | $5.1M | $4.9M | $4.8M | $4.7M | $3.8M | $3.0M | $2.5M | — |
| Stock-based compensation | $8.9M | $7.8M | $5.4M | $3.1M | $10.0M | $8.3M | $3.4M | $2.4M | $2.3M | — |
| Capital expenditure | $12.0M | $9.0M | $8.1M | $14.2M | $6.3M | $7.3M | $6.7M | $3.6M | $3.1M | — |
| Investing cash flow | -$228.0M | -$70.7M | -$30.2M | -$24.2M | -$20.1M | -$41.6M | -$26.5M | -$9.5M | -$16.1M | — |
| Financing cash flow | $172.5M | $49.6M | $1.1M | $12.1M | $43.5M | -$8.9M | $17.3M | -$13.8M | -$1.2M | — |
| Dividends paid | — | — | — | — | $0 | $0 | $11.6M | $0 | $0 | — |
| Buybacks | — | — | — | $0 | $0 | $65.0K | $0 | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001766400-26-000014.
Others in SIC 8000
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | $4.86B | — | 13.9% |
| PRVA | Privia Health Group, Inc. | $2.64B | 114.8x | 22.3% |
| WGS | GeneDx Holdings Corp. | $2.56B | — | 40.0% |
| INNV | InnovAge Holding Corp. | $1.46B | — | 11.8% |
| OMDA | Omada Health, Inc. | $1.39B | — | 53.2% |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.18B | 55.9x | 16.3% |
| SRTA | Strata Critical Medical, Inc. | $470.6M | 10.6x | 34.3% |
| DCGO | DocGo Inc. | $39.8M | — | -47.7% |